Named after the hundred-eyed watchman of Greek myth, Argus watches the education landscape: spotting new opportunities, pressure-testing the ventures we're building, and tracing every read back to the real-world signals behind it.
The evidence library: the raw signals the pipeline is watching across the education ecosystem. Every idea is built from these.
The Family and Youth Services Bureau's (FYSB) Runaway and Homeless Youth Division has a legislative requirement to fund a National Communication System, which is currently operated by the National Runaway Safeline (NRS). The NRS provides information, referral services, crisis intervention, and prevention resources to vulnerable youth at risk of running away and/or becoming homeless and their families or legal guardians at no cost. When necessary, the NRS refers runaway and homeless youth to shelters, counseling, medical assistance, and other vital services. The NRS collects information from all contacts with youth and adults connecting with the NRS (i.e., parents, family members, legal guardians, service providers) on a voluntary basis to inform crisis services and develop an annual report on the information collected during calls, chats, emails, and forum posts from young people who reached out to the NRS's crisis services. This information collection is approved under Office of Manag
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a final guidance for industry (GFI) #152 entitled "Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern." This guidance document informs interested parties about FDA's current method for evaluating potential microbiological effects of antimicrobial new animal drugs on bacteria of human health concern as part of the new animal drug application process.
The Food and Drug Administration (FDA) is classifying the fludeoxyglucose F18-guided radiation therapy system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the fludeoxyglucose F18-guided radiation therapy system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
The Food and Drug Administration (FDA or Agency) is announcing the issuance of an Emergency Use Authorization (EUA) (the Authorization) under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in response to an outbreak of Mpox. FDA has issued an Authorization for an in vitro diagnostic device, Allplex HSV-1&2/VZV/ MPXV Assay, for the simultaneous qualitative detection and differentiation of viral nucleic acid from monkeypox virus (MPXV clade I/II and MPXV clade II)1, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV). The Authorization contains, among other things, conditions on the emergency use of the authorized product. The Authorization follows the August 9, 2022, determination by the Secretary of Health and Human Services (HHS) that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled HIV Capacity Building Assistance (CBA) Program: Data Management, Monitoring, and Evaluation. This data collection aims to determine the short- and long-term outcomes of the CDC HIV CBA program and support continuous quality improvement.
In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
The ACF, ORR announces the intent to award a single-source cooperative agreement in an amount of up to $150,000,000 to Burke Law Group, a law firm headquartered in Houston, Texas. The purpose of this proposed award is to provide legal orientation, legal consultation, and attorney-of-record representation services for eligible unaccompanied alien children (UACs) during immigration proceedings before the Executive Office for Immigration Review (EOIR) and in hearings and proceedings before the U.S. Citizenship and Immigration Services (USCIS) while children remain in ORR care. The proposed award also includes limited discharge-related legal continuity planning and referral support for children exiting ORR care. Under the proposed award, Burke Law Group would provide legal orientation, legal consultation, and attorney-of-record representation services for eligible UACs while they remain in ORR care. The recipient would also provide limited discharge-related legal continuity planning and re
In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing an extension without change of a currently approved information collection request (ICR).
In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a revision of a currently approved information collection request (ICR).
In accordance with the Paperwork Reduction Act (PRA) of 1995, the Department is proposing a new information collection request (ICR).
The Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS), is inviting public comments on the proposed revisions to an information collection. The Monitoring and Compliance for ORR Care Provider Facilities information collection consists of several forms that will allow the Monitoring and Compliance Bureau (MCB) and Unaccompanied Alien Children Bureau (UACB) to better monitor UACB- funded care provider facilities for compliance with federal and state laws and regulations, licensing and accreditation standards, ORR policies and procedures, and child welfare standards. This request includes the addition of nine new instruments, discontinuation of obsolete instruments, and revisions to remaining currently approved instruments.
The Office of Refugee Resettlement (ORR) is requesting a 3- year extension with revisions of the Unaccompanied Refugee Minors (URM) Program ORR-3 Report and ORR-4 Report (Office of Management and Budget #: 0970-0034, expiration November 30, 2026). Revisions were made to reduce burden and streamline information collection.
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
The Administration for Children and Families (ACF) Office of Refugee Resettlement (ORR) is requesting to move the Serious Medical Procedure Request (SMR) Form (Office of Management and Budget (OMB) #: 0970-0561, expiration date December 31, 2026) under the Medical Assessment Form and Dental Assessment Form (OMB #: 0970-0466, expiration October 31, 2026) information collection and update the title of OMB # 0970-0466 to Office of Refugee Resettlement (ORR) Unaccompanied Alien Child Health Forms. Revisions are proposed to the forms. The proposed restructuring and revisions will improve transparency, lessen burden, improve data quality, and ensure alignment with ORR requirements. In addition, to ensure continuity of care, the request has been revised to include the sharing of health information with the Department of Homeland Security (DHS) in specific circumstances.
The Administration for Children and Families (ACF) proposes to extend data collection under the existing overarching generic clearance for Formative Data Collections for ACF Research and Evaluation (Office of Management and Budget (OMB)#: 0970-0356). There are no changes proposed to the intended purpose or use of the potential data collections, but burden has been adjusted to reflect agency priorities.
In accordance with the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS) is providing notice of the re-establishment of a matching program between CMS and the Department of War for "Verification of Eligibility for Minimum Essential Coverage Under the Patient Protection and Affordable Care Act through a Department of War Health Benefits Plan."
The Center for Drug Evaluation and Research (CDER) within the Food and Drug Administration (FDA or Agency), through its Quantitative Medicine Center of Excellence (QM CoE), is announcing a request for information to inform the development of a Quantitative Medicine Innovation Network (QMIN). The vision for the QMIN is to create a cross-sector collaborative platform that accelerates the translation of quantitative medicine approaches to transform drug development, regulatory science, and clinical decision-making for patient benefit. The purpose of this request is to obtain feedback from industry, academia, healthcare providers, patient groups, and other interested parties on identifying critical community needs and establishing mechanisms for continuous engagement, supporting collaborative demonstration projects or research on innovative approaches aimed at addressing high priority areas through the application of QM approaches, and exploring mechanisms to leverage community expertise a
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces nine separate awards to fund Institut National Hygiene Publique, Cote d'Ivoire; Ministry of Health-Centers for Disease Control and Prevention, Egypt; Ethiopian Public Health Institute; Noguchi Memorial Institute for Medical Research, Ghana; Institut National d Hygiene, Morocco; Institut Pasteur de Dakar, Senegal; Institut Pasteur de Tunis, Tunisia; Uganda Virus Research Institute; University Teaching Hospital, Zambia. For Institut National Hygiene Publique, Cote d'Ivoire, the award is for approximately $800,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Ministry of Health-Centers for Disease Control and Prevention, Egypt, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For Ethiopian Public Health Institute, the award is for approximately $800,000 in FFY 2026, subject to the availabi
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces five separate awards to fund HEADA Cameroon; Instituto Nacional de Saude, Mozambique; Nigeria Centre for Disease Control and Prevention; National Institute of Health, Pakistan; Kinshasa School of Public Health, Democratic Republic of the Congo. For Association HEADA Cameroon, the award is for approximately $600,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Instituto Nacional de Saude, Mozambique, the award is for approximately $900,000 in FFY 2026, subject to the availability of funds. For Nigeria Centre for Disease Control and Prevention, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For National Institute of Health, Pakistan, the award is for approximately $800,000 in FFY 2026, subject to the availability of funds. For Kinshasa School of Public Health, Democratic Republic of th
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces six separate awards to fund the Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran, Argentina; Instituto de Salud Publica de Chile, Chile; Ministerio de Salud P[uacute]blica de Ecuador, Ecuador; Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama; Alter Vida Centro De Estudios Y Formaci[oacute]n Para Ecodesarrollo, Paraguay; Caribbean Public Health Agency, Caribbean Region. For Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran, Argentina, the award is for approximately $600,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For Instituto de Salud Publica de Chile, Chile, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Ministerio de Salud P[uacute]blica de Ecuador, Ecuador, the award is for approximately $800,0
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces four separate awards to fund the Ministry of Health, Bhutan; National Influenza Center, Mongolia; Research Institute for Tropical Medicine, Philippines; Bangkok Metropolitan Administration, Thailand. For Ministry of Health, Bhutan, the award is for approximately $800,000 in Federal Fiscal Year (FFY) 2026, subject to the availability of funds. For National Influenza Center, Mongolia, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Research Institute for Tropical Medicine, Philippines, the award is for approximately $600,000 in FFY 2026, subject to the availability of funds. For Bangkok Metropolitan Administration, Thailand, the award is for approximately $900,000 in FFY 2026, subject to the availability of funds. The total FFY 2026 funding amount for the four recipients is $2,900,000. Funding amounts for years 2-
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund the Universidad Peruana Cayetano Heredia for approximately $600,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund The Task Force for Global Health for approximately $4,000,000, in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund HJF Medical Research International, Inc., Kenya, for approximately $1,000,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fondacioni SECID, Balkan Region, for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces one award to fund Fundacion Mexico-Estados Unidos Para La Ciencia, A.C. for approximately $800,000 in Federal Fiscal Year 2026, subject to the availability of funds. Funding amounts for years 2-5 will be set at continuation.
The Food and Drug Administration (FDA or we) received objections and requests for a public hearing submitted by Buchanan Ingersoll & Rooney PC, on behalf of Micro-Tracers, Inc. (Micro-Tracers or objector), on the order granting a color additive petition (3C0323) requesting that we repeal specified regulations to no longer provide for the safe use of FD&C Red No. 3 in food (including dietary supplements) and ingested drugs. After reviewing the objections, we have concluded that the objections do not raise issues of material fact that justify a hearing. We are also providing notice that the administrative stay of the effective date for the repeal and delisting of the color additive regulations is now lifted.
This meeting notice announces the virtual meeting public components of the Healthcare Advisory Committee (HAC or Committee) for the fiscal year 2026-2027. The purpose of the Committee is to advise the Secretary of HHS and the CMS Administrator on programs and policies that can improve the United States healthcare system consistent with the Executive Order Establishing the President's Make American Healthy Again Commission. The virtual meetings are open to the public.
This final rule will revise the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; make changes relating to Medicare graduate medical education (GME) for teaching hospitals; update the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); update and make changes to requirements for certain quality programs; and make other policy- related changes. ONC also adopts certain health information technology (health IT) standards and specifications on behalf of HHS.
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry titled "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs." This revised draft guidance provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation (and sensitization, if applicable) potential of a proposed transdermal or topical delivery system (collectively referred to as TDS). The recommendations in this revised draft guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The revised draft guidance is intended to clarify FDA's recommendations and expectations related to in vivo skin irritation and in vivo combined skin irritation and sensitization studies. This draft guidance replaces the draft guidance "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs" (April 2023).
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs." This guidance provides recommendations for the design and conduct of studies evaluating the adhesion performance of a transdermal or topical delivery system (collectively referred to as TDS). Depending on the objectives of a generic TDS product development program, applicants may choose to evaluate TDS adhesion in studies performed to evaluate TDS adhesion only, or in studies performed with a combined purpose (e.g., for the simultaneous evaluation of adhesion and bioequivalence (BE) with pharmacokinetic (PK) endpoints). The recommendations in this guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The guidance replaces the draft guidance (Revision 2) "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs," issued on April 13, 2
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts." This draft guidance is intended to help applicants develop container closure systems and device constituent parts for proposed biosimilar and interchangeable biosimilar products. This draft guidance expands on and clarifies the Agency's recommendations and expectations regarding the development of delivery devices and container closure systems described in Q.I.4 of the guidance for industry entitled "Questions and Answers on Biosimilar Development and the BPCI Act" and the guidance for industry entitled "Considerations in Demonstrating Interchangeability With a Reference Product" for biosimilar and interchangeable biosimilar products, respectively.
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternati
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Angela Anatilde Baquero from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Angela Anatilde Baquero was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mrs. Baquero was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mrs. Baquero has not responded. Mrs. Baquero's failure to respond and request a hearing constitutes a waiver of Mrs. Baquero's right to a hearing concerning this matter.
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Ricardo Andres Acuna from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Ricardo Andres Acuna was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mr. Acuna was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mr. Acuna has not responded. Mr. Acuna's failure to respond and request a hearing constitutes a waiver of Mr. Acuna's right to a hearing concerning this matter.
The Department of Health and Human Services (HHS) provides notice of the laboratories and Instrumented Initial Testing Facilities (IITFs) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines) using Urine and the laboratories currently certified to meet the standards of the Mandatory Guidelines using Oral Fluid.
This final rule updates the prospective payment rates for inpatient rehabilitation facilities (IRFs) for Federal fiscal year (FY) 2027. As required by statute, this final rule includes the classification and weighting factors for the IRF prospective payment system's (PPS) case-mix groups and a description of the methodologies and data used in computing the prospective payment rates for FY 2027. It also finalizes the third and final of the 3-year phaseout of the rural adjustment, which began in FY 2025. This final rule includes a solicitation for public comments on alternative data sources for the IRF PPS wage index; requires all therapy treatments and/or therapy evaluations to begin no later than 36 hours from midnight on the day of admission; finalizes requirements for the initial Interdisciplinary Team meeting to occur on or before 4 days from the date the patient is admitted; and summarizes a request for information on potential future IRF PPS payment reform. Additionally, this fina